Concurrent Investment Advisors LLC Trims Holdings in Sanofi (NASDAQ:SNY)

Concurrent Investment Advisors LLC trimmed its holdings in Sanofi (NASDAQ:SNY - Free Report) by 74.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,700 shares of the company's stock after selling 28,246 shares during the quarter. Concurrent Investment Advisors LLC's holdings in Sanofi were worth $538,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the business. Golden State Wealth Management LLC increased its stake in Sanofi by 619.3% in the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock valued at $35,000 after buying an additional 545 shares during the period. Bessemer Group Inc. increased its stake in Sanofi by 59.8% in the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after buying an additional 242 shares during the period. Lee Danner & Bass Inc. acquired a new position in Sanofi in the 4th quarter valued at $31,000. UMB Bank n.a. increased its stake in Sanofi by 30.7% in the 1st quarter. UMB Bank n.a. now owns 1,124 shares of the company's stock valued at $62,000 after buying an additional 264 shares during the period. Finally, Wayfinding Financial LLC acquired a new position in Sanofi in the 1st quarter valued at $63,000. 14.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Price Performance

Shares of NASDAQ:SNY traded down $0.73 on Friday, reaching $48.61. 1,207,445 shares of the company were exchanged, compared to its average volume of 2,330,352. The company has a current ratio of 1.37, a quick ratio of 0.69 and a debt-to-equity ratio of 0.16. Sanofi has a 1-year low of $45.80 and a 1-year high of $60.12. The firm has a market cap of $119.21 billion, a price-to-earnings ratio of 17.36, a price-to-earnings-growth ratio of 1.11 and a beta of 0.48. The company has a 50-day moving average of $50.05 and a 200-day moving average of $52.11.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.90 by $0.04. Sanofi had a net margin of 14.56% and a return on equity of 17.15%. The business had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. During the same period in the previous year, the firm earned $1.78 EPS. The business's revenue for the quarter was down 11.0% compared to the same quarter last year. Equities analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The firm also recently disclosed an annual dividend, which was paid on Thursday, June 12th. Investors of record on Friday, May 9th were given a $2.0369 dividend. The ex-dividend date was Friday, May 9th. This is a positive change from Sanofi's previous annual dividend of $1.48. This represents a dividend yield of 3.1%. Sanofi's payout ratio is currently 57.14%.

Analysts Set New Price Targets

SNY has been the topic of several recent research reports. Hsbc Global Res raised shares of Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. Morgan Stanley set a $56.00 price objective on shares of Sanofi in a research note on Monday, June 2nd. Barclays reissued an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. Guggenheim reaffirmed a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Finally, BNP Paribas assumed coverage on shares of Sanofi in a research note on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price target on the stock. Three analysts have rated the stock with a hold rating, four have given a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $61.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.